Formulation Development
Studies Validate Advantages of Administering Drugs to Pets Via IntelGenx’s VetaFilm Platform
IntelGenx Corp. recently announced positive results from a proof-of-concept (POC) study to assess the palatability, owner-perceived acceptability, and ease of repeated administration of IntelGenx’s VetaFilm…
Biovian & 3P Biopharmaceuticals Join Forces to Create 3PBIOVIAN
Biovian and 3P Biopharmaceuticals, two leading biologics Contract Development and Manufacturing Organizations (CDMOs), recently announced their combination to establish a new pan-European leader in their….
Purple Biotech Reaches Recommended Phase 2 Dose for NT219
Purple Biotech Ltd. recently announced it has determined 100mg/kg is the recommended Phase 2 dose (RP2D) for NT219 in combination with cetuximab in the treatment…
Denali Therapeutics Announces Presentations on its Investigational Blood-Brain Barrier-Crossing Enzyme Replacement Therapies
Denali Therapeutics Inc. recently announced upcoming presentations from its Enzyme Transport Vehicle (ETV) development programs, tividenofusp alfa (DNL310) and DNL126 (ETV:SGSH), to be given at…
Ascendia Pharmaceuticals Expanding Injectable Manufacturing Capabilities in 2024
Ascendia Pharmaceuticals is all set to unveil its new injectables manufacturing opportunities with the launch of a state-of-the-art sterile cGMP production facility in March 2024…..
AustinPx Partners With Microsize on KinetiSol Technology, Partnership Strengthens Commercialization Options for AustinPx’s Clients
AustinPx and Microsize recently announced the strategic partnership to accelerate the commercial application of AustinPx’s KinetiSol Technology platform. The collaboration will enable….
Kindeva Drug Delivery Launches New Analytical Services Global Business Unit
Kindeva Drug Delivery recently announced the expansion of its analytical services capabilities — launching a new global business unit offering integrated and stand-alone analytical support to…
BioNTech & DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate
BioNTech SE and Duality Biologics recently announced the US FDA granted Fast Track designation for BNT325/DB-1305 for the treatment of patients with platinum-resistant ovarian epithelial cancer….
Cristalia Products With Nemera’s Reusable Pen Injector Commercialized in Brazil
Cristalia’s human growth hormone will be administered with CRISPEN. Approved by ANVISA1, CRISPEN is part of Nemera’s state-of-the-art pen injector platform PENDURA AD……..
Iterum Therapeutics Announces Positive Topline Results from its Phase 3 Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
Iterum Therapeutics plc recently announced positive topline results from its REASSURE (REnewed ASsessment of Sulopenem in uUTI caused by Resistant Enterobacterales) Phase 3 clinical trial comparing oral sulopenem (sulopenem etzadroxil…
Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases With University of Florida
Vaxxinity, Inc. recently announced a research collaboration with the University of Florida’s (UF) Center for Translational Research in Neurodegenerative Disease (CTRND) to support its work on…
Jnana Therapeutics Announces Positive Clinical Proof of Concept Achieved With Potential First-in-Class Oral Treatment for PKU
Jnana Therapeutics recently announced positive, statistically significant interim results from its ongoing clinical study of JNT-517 in individuals with phenylketonuria (PKU). JNT-517, a small molecule inhibitor…
Oxford Biomedica Completes Acquisition of ABL Europe
The acquisition of ABL Europe, a pure-play European CDMO, strengthens Oxford Biomedica’s position as a world-leading cell and gene therapy CDMO. This strategic move broadens….
Longeveron Receives Notice of US Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B
Longeveron Inc. recently announced it received a notice of patent allowance from the United States Patent and Trademark Office (PTO) for Medicinal Signaling Cells (MSCs),…
First Patient Dosed With LIXTE’s LB-100 & GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial
LIXTE Biotechnology Holdings, Inc. recently announced the dosing of the first patient in a Phase 1b/2 clinical trial to assess whether adding LIXTE’s LB-100 to GSK’s…
SPECIAL FEATURE - Outsourcing Analytical Testing: AI Could Transform Analytical Labs
Contributor Cindy H. Dubin presents how today’s leading analytical testing service providers are taking advantage of AI and other types of automation and innovative technologies.
EXECUTIVE INTERVIEW - How Resilience Is Bringing Forward Thinking to Disrupt the Biomanufacturing Landscape to Increase Access to Medicines
Syed T. Husain, Chief Commercial Officer of Resilience, discusses how the company became an industry-leading service provider in less than 4 years.
FORMULATION FORUM - Lipid Nanoparticles – Carriers for Nucleic Acids Delivery
Shaukat Ali, PhD, and Jim Huang, PhD, describe the role of individual components in aggregation, packing, stability, efficacy, and potency of nucleic acids, the understanding of which is important to achieve better designed and smarter formulations, and robust scale up and manufacturing of LNPs.
SPECIAL ROUNDTABLE - Leadership Panel: 4 Trends That Will Have the Most Impact on Drug Development in 2024
Contributor Cindy H. Dubin asked some of today’s life science leaders what they expect will have the greatest impact on drug development in 2024 and beyond.
DRUG DISCOVERY - Overcoming Traditional Challenges: Innovative Chemoproteomics Strategies to Revolutionize Drug Discovery
Ping Cao, PhD, and Irene Yuan believe their chemoproteomic platform offers a distinct advantage by enabling the simultaneous exploration of the entire proteome, setting it apart from other drug discovery technologies that typically focus on individual targets.
